- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04647253
Um ensaio clínico para avaliar o cateter de balão de PTCA revestido com paclitaxel para o tratamento de indivíduos com reestenose intra-stent (ISR) (AGENT IDE)
AGENT IDE: Um estudo prospectivo, randomizado (2:1) multicêntrico para avaliar a segurança e a eficácia do cateter de balão de PTCA revestido com paclitaxel AgentTM para o tratamento de indivíduos com reestenose intra-stent (ISR)
AGENT IDE is a Prospective, Randomized (2:1), Multicenter Trial. The purpose of this study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter compared to balloon angioplasty (POBA) in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 26 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85745
- Carondelet Medical Group St. Mary's Hospital
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- University of California San Diego
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai Medical Center
-
San Francisco, California, Estados Unidos, 94121
- San Francisco Veterans Affairs Medical Center
-
Stanford, California, Estados Unidos, 94305
- Stanford University Medical Center
-
-
Colorado
-
Lakewood, Colorado, Estados Unidos, 80216
- St. Anthony Hospital
-
Littleton, Colorado, Estados Unidos, 80210
- South Denver Cardiology
-
-
Florida
-
Tallahassee, Florida, Estados Unidos, 32308
- Tallahassee Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital
-
Lawrenceville, Georgia, Estados Unidos, 30046
- Northside Hospital
-
Marietta, Georgia, Estados Unidos, 30060
- Wellstar Kennestone Hospital
-
-
Illinois
-
Evanston, Illinois, Estados Unidos, 60201
- Evanston Hospital
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66211
- Overland Park Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- St. Luke's Hospital of Kansas City
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68124
- Bergan Cardiology
-
-
New Jersey
-
Neptune City, New Jersey, Estados Unidos, 07753
- Jersey Shore University Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
Roslyn, New York, Estados Unidos, 11576
- St. Francis Hospital
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos, 27610
- Wake Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Lindner Center for Research and Education at Christ Hospital
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Wormleysburg, Pennsylvania, Estados Unidos, 17053
- UPMC Pinnacle Health
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38104
- Methodist North Hospital
-
Nashville, Tennessee, Estados Unidos, 37203
- Centennial Medical Center
-
-
Texas
-
Austin, Texas, Estados Unidos, 78756
- Heart Hospital of Austin
-
Dallas, Texas, Estados Unidos, 75226
- Baylor Heart and Vascular Hospital
-
Houston, Texas, Estados Unidos, 77030
- Houston Methodist Hospital
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Medical Center
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Fairfax Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Clinical Inclusion Criteria
- Subject must be at least 18 years of age
- Subject (or legal guardian) understands the trial requirements and the treatment procedures, and provides written informed consent before any trial-specific tests or procedures are performed
- Subject is eligible for percutaneous coronary intervention (PCI)
- Subject is willing to comply with all protocol-required follow-up evaluation
- Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure
Angiographic Inclusion Criteria (visual estimate)
-
In-stent restenosis in a lesion previously treated with either a drug-eluting stent or bare metal stent, located in a native coronary artery with a visually estimated reference vessel diameter (RVD) > 2.0 mm and ≤ 4.0 mm.
-
Target lesion length must be < 26 mm (by visual estimate) and must be covered by only one balloon.
-
Target lesion must have visually estimated stenosis > 50% and < 100% in symptomatic patients (>70% and <100% in asymptomatic patients) prior to lesion pre-dilation.
-
Target lesion must be successfully pre-dilated.
o Note: Successful predilation/pretreatment refers to dilation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C. Thrombolysis in Myocardial Infarction (TIMI) grade flow in the target lesion must be >2
-
If a non-target lesion is treated, it must be treated first and must be deemed a success.
- Note: Successful treatment of a non-target lesion is defined as a residual stenosis of ≤ 30% in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician, without the occurrence of prolonged chest pain or ECG changes consistent with MI.
Clinical Exclusion Criteria
- Subject has other serious medical illness (e.g. cancer, congestive heart failure) that may reduce life expectancy to less than 24 months.
- Subject has current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc.).
- Subject has planned procedure that may cause non-compliance with the protocol or confound data interpretation.
- Subject is participating in another investigational drug or device clinical study that has not reached its primary endpoint.
- Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure.
- Woman who is pregnant or nursing. (A pregnancy test must be performed within 7 days prior to the index procedure, except for women who definitely do not have child-bearing potential.)
- Left ventricular ejection fraction known to be < 25%.
- Subject had PCI or other coronary interventions within the last 30 days.
- Planned PCI or CABG after the index procedure.
- STEMI or QWMI <72h prior to the index procedure.
- Cardiogenic shock (SBP < 80 mmHg requiring inotropes, IABP or fluid support).
- Known allergies against paclitaxel or other components of the used medical devices.
- Known hypersensitivity or contraindication for contrast dye that in the opinion of the investigator cannot be adequately pre-medicated.
- Intolerance to antiplatelet drugs, anticoagulants required for procedure.
- Platelet count < 100k/mm3 (risk of bleeding) or > 700k/mm3.
- Subject with renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent).
- Subject has suspected or proven COVID-19 at present or within the past 4 weeks with resolution of symptoms.
Angiographic Exclusion Criteria (visual estimate)
- Target lesion is located within a bifurcation with planned treatment of side branch vessel.
- Target lesion is located within a saphenous vein or arterial graft.
- Thrombus present in the target vessel
- > 50% stenosis of an additional lesion proximal or clinically significant distal (>2.0mm RVD) to the target lesion.
- Patient with unprotected left main coronary artery disease. (>50% diameter stenosis)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Comercialmente disponível, cateter de dilatação PTCA
|
PTCA balloon catheter |
|
Experimental: AGENT DCB
Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391). |
Drug coated PTCA balloon catheter |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Target Lesion Failure
Prazo: 12-month
|
The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death |
12-month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Robert Yeh, MD, Beth Israel Deaconess Medical Center
Publicações e links úteis
Publicações Gerais
- Yeh RW, Bachinsky W, Stoler R, Bateman C, Tremmel JA, Abbott JD, Dohad S, Batchelor W, Underwood P, Allocco DJ, Kirtane AJ. Rationale and design of a randomized study comparing the agent drug coated balloon to plain old balloon angioplasty in patients with In-stent restenosis. Am Heart J. 2021 Nov;241:101-107. doi: 10.1016/j.ahj.2021.07.008. Epub 2021 Jul 24.
- Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Bateman C, Krishnaswamy A, Grantham JA, Zidar FJ, Marso SP, Tremmel JA, Grines C, Ahmed MI, Latib A, Tehrani B, Abbott JD, Batchelor W, Underwood P, Allocco DJ, Kirtane AJ; AGENT IDE Investigators. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial. JAMA. 2024 Mar 26;331(12):1015-1024. doi: 10.1001/jama.2024.1361.
- Kirtane AJ, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Bateman C, Krishnaswamy A, Grantham JA, Zidar FJ, Tremmel JA, Grines C, Ahmed MI, Latib A, Tehrani B, Abbott JD, Batchelor W, Cavalcante R, Yeh RW. Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis. J Am Coll Cardiol. 2025 Aug 19;86(7):502-511. doi: 10.1016/j.jacc.2025.05.062.
- Wen J, Dohad S, Shlofmitz R, Moses J, Bachinsky W, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Neupane S, Croce K, Shunk K, Taylor A, Saybolt MD, Diaz C, Cavalcante R, Yeh RW, Kirtane AJ. Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial. JACC Cardiovasc Interv. 2025 Nov 24;18(22):2701-2710. doi: 10.1016/j.jcin.2025.09.032.
- Jamil Y, Kirtane A, Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Krishnaswamy A, Alaswad K, Kimmelstiel C, Reitman A, Cavalcante R, Tehrani BN, Batchelor WB. Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. J Am Heart Assoc. 2026 Jan 20;15(2):e043053. doi: 10.1161/JAHA.125.043053. Epub 2026 Jan 19.
- Abbott JD, Kassis N, Latib A, Shlofmitz RA, Moses JW, Bachinsky WB, Dohad S, Rudick SG, Stoler RC, Jefferson BK, Nicholson WJ, Altman JD, Bateman CT, Krishnaswamy A, Cavalcante R, Yeh RW, Kirtane AJ. Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial. Circ Cardiovasc Interv. 2026 Aug 6:e016289. doi: 10.1161/CIRCINTERVENTIONS.125.016289. Online ahead of print.
- Tehrani BN, Vavilin I, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Bateman C, Tremmel JA, Abbott JD, Batchelor W, Cavalcante R, Yeh RW, Kirtane AJ. Influence of Chronic Kidney Disease on Outcomes After Paclitaxel-Coated Balloon Angioplasty for Coronary In-Stent Restenosis. Circ Cardiovasc Interv. 2026 Sep 17:e016978. doi: 10.1161/CIRCINTERVENTIONS.126.016978. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- S2358
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .